TBPH Theravance Biopharma Inc.

16.81
0  0%
Previous Close 16.81
Open
Price To Book -8.32
Market Cap 943,665,912
Shares 56,137,175
Volume 0
Short Ratio
Av. Daily Volume 285,540

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released September 20, 2017 - primary endpoint met.
Closed Triple - IMPACT
COPD
Approved June 21, 2013.
VIBATIV (telavancin hydrochloride) for injection
Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP)
Approved April 30, 2015.
BREO ELLIPTA
Asthma
Phase 3 initiation of dosing announced January 28, 2019.
Ampreloxetine (TD-9855)
nOH
Phase 3 data released May 2, 2019 met primary but missed key secondary endpoint.
Closed Triple - CAPTAIN
Asthma
Approval announced September 19, 2017.
Closed Triple
COPD
FDA Approval announced November 9, 2018.
Revefenacin
COPD
Phase 2b data released August 2, 2017. Primary endpoint not met.
Velusetrag (TD-5108)
Gastroparesis
Phase 2 data released June 2016
TD-6450
Hepatitis C virus (HCV)
Phase 3 trial discontinued following recent interim analysis.
Telavancin
Bacteremia
Phase 3 first patient enrolled late February 2015. Data due 2017
Telavancin
Staphylococcus aureus bacteremia
Phase 3 data due in 2016
TD-4208
Chronic obstructive pulmonary disease (COPD
Phase 2 commencement of dosing announced November 21, 2018.
TD-1473
Crohn's Disease
Phase 2b/3 initiation of dosing announced March 12, 2019.
TD-1473
Ulcerative Colitis
Phase 1 data due 3Q 2019.
TD-8236
Asthma

Latest News

  1. See what the IHS Markit Score report has to say about Theravance Biopharma Inc.
  2. Introducing Theravance Biopharma (NASDAQ:TBPH), The Stock That Slid 54% In The Last Five Years
  3. The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
  4. Theravance Bio (TBPH) Down 27.7% Since Last Earnings Report: Can It Rebound?
  5. Theravance Biopharma Appoints Andrew Hindman as Senior Vice President and Chief Financial Officer
  6. Lilly's Crohn's Disease Candidate Meets Phase II Study Goals
  7. Theravance Biopharma Reports Data from Phase 1b Study of TD-1473 in Oral Presentation at Digestive Disease Week (DDW) 2019
  8. Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International Conference
  9. Theravance Biopharma Inc. (TBPH) Q1 2019 Earnings Call Transcript
  10. Edited Transcript of TBPH earnings conference call or presentation 7-May-19 9:00pm GMT
  11. Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 to be Featured in Oral Presentation at Digestive Disease Week (DDW) 2019
  12. Theravance (TBPH) Q1 Loss Widens, Revenues Miss Estimates
  13. Theravance Biopharma (TBPH) Reports Q1 Loss, Lags Revenue Estimates
  14. Theravance Bio: 1Q Earnings Snapshot
  15. Theravance Biopharma, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update
  16. Here’s What Hedge Funds Think About Theravance Biopharma Inc (TBPH)